fda import alert glp-1 semaglutide tirzepatide green list Establishes 'Green List' to Protect US Supply FDA warns against compounded GLP-1

doi:10.2337/dc19-0883 Data on file

Common reported effects in clinical use include mild injection site reactions with subcutaneous administration, occasional digestive changes when taken orally, and rare reports of fatigue or dizziness

J Hematol Oncol (2021) 14(1):14

Prunella vulgaris total flavonoids have been confirmed to have an obvious antihepatocarcinoma effect, and the mechanism may be linked to the inhibition of autophagy which may be related to activation of the PI3K/Akt/mTOR pathway (Song et al., 2021)

Open communication with healthcare providers about fertility intentions ensures semaglutide therapy supportsrather than complicatesfamily planning